The blister pack used in MDT of leprosy Is shown in PLATE. Which drug is not supplied in it?
## **Core Concept**
The multidrug therapy (MDT) for leprosy, as recommended by the World Health Organization (WHO), consists of a combination of rifampicin, clofazimine, and dapsone. This regimen is aimed at effectively treating leprosy and preventing drug resistance.
## **Why the Correct Answer is Right**
The MDT blister pack for leprosy typically contains rifampicin (R), dapsone (D), and clofazimine (C). These drugs work synergistically to target the causative agent of leprosy, *Mycobacterium leprae**. Rifampicin is a potent bactericidal agent against *M. leprae*, dapsone has bacteriostatic properties, and clofazimine has both bactericidal and anti-inflammatory effects.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because the specific drugs listed are not provided, but based on the context, we know rifampicin is part of MDT.
- **Option B:** Similarly, this option cannot be evaluated directly, but clofazimine is a component of MDT.
- **Option D:** Dapsone is also a component of the MDT regimen.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the standard MDT regimen for leprosy includes rifampicin, dapsone, and clofazimine. This combination is crucial for effective treatment and to prevent the development of drug resistance.
## **Correct Answer:** .